This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
3rd August 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake
	(Security Code: 190A TSE Growth Market)
Contact:	IR Manager Ami Kira
MAIL :	info@chordiatherapeutics.com

Announcement of Publication of Collaborative Research Findings on MALT1

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") today announced that research findings on MALT1 from collaborative research with Miyazaki University, Kyoto University, the National Cancer Center Japan, and other institutions were published in *iScience*, an international scientific journal published by Cell Press, on July 23, 2026.

Summary

Adult T-cell leukemia/lymphoma (ATL) is a T-cell hematologic malignancy that develops in the context of HTLV-1 infection. In Japan, many patients are found in the Kyushu and Okinawa regions, and ATL remains a challenging disease for which new treatment options are still needed.

In this study, the role of MALT1 in ATL was analyzed using tool compounds that inhibit MALT1. The results suggested that MALT1 activity is important for tumor growth in certain ATL cell lines and ATL patient-derived xenograft models. In these models, MALT1 inhibition also demonstrated antitumor effects. These findings are based on preclinical research. The efficacy and safety of MALT1 inhibitors in patients with ATL remain to be evaluated through further research and development.

This study suggests that MALT1 may represent a therapeutic target in a subset of ATL and provides valuable insights that may contribute to the further advancement of Chordia's MALT1 inhibitor research and development efforts.

Publication Details

The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma
iScience, Jul. 23, 2026
URL: https://www.cell.com/iscience/fulltext/S2589-0042(26)02228-5

About the Journal

iScience is an open-access international scientific journal published by Cell Press. It covers a broad range of research fields, including the life sciences, physical sciences, and earth sciences, and publishes basic and applied research that contributes to the advancement of each field.

Glossary of Terms

Term	Explanation
MALT1	Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). Activation of MALT1 has been reported to play an important role in hematologic malignancies, including certain leukemias and lymphomas. Inhibition of MALT1 activity is expected to exert antitumor effects against these hematologic cancers.
HTLV-1	Human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 is a retrovirus transmitted mainly through mother-to-child transmission, sexual contact, and blood transfusion. It is known that a subset of infected individuals develops diseases such as ATL.

This collaborative research was led by Professor Seishi Ogawa of the Graduate School of Medicine, Kyoto University, and was supported by the Acceleration Transformative Research for Medical Innovation (ACT-M) Program of the Japan Agency for Medical Research and Development (AMED).

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.